Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma

Alberto Broniscer, Sharyn D. Baker, Cynthia Wetmore, Atmaram S. Pai Panandiker, Jie Huang, Andrew M. Davidoff, Arzu Onar-Thomas, John C. Panetta, Thomas K. Chin, Thomas E. Merchant, Justin N. Baker, Sue C. Kaste, Amar Gajjar, Clinton F. Stewart

Research output: Contribution to journalArticle

47 Scopus citations

Abstract

Purpose: Testing of promising drug combinations is crucial in the treatment of diffuse intrinsic pontine glioma (DIPG). As the VEGF and platelet-derived growth factor (PDGF) pathways are critical in gliomas, we evaluated the safety, maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of vandetanib, a VEGFR-2 inhibitor, combined with dasatinib, a potent PDGFR inhibitor, during and after radiotherapy in children with newly diagnosed DIPG. Experimental Design: Dasatinib was started concurrently with radiotherapy. Vandetanib was started 8 days later. We tested increasing doses of vandetanib (65 and 85 mg/m2 once daily) and dasatinib (65 and 85 mg/m 2 twice daily). Dose-limiting toxicities were evaluated during the first 6 weeks of therapy. Plasma pharmacokinetics was obtained on days 8 and 42 ± 3 in all patients and concomitantly with cerebrospinal fluid (CSF) when possible. Inhibition of targets of dasatinib in peripheral blood mononuclear cells (PBMC) was evaluated. Results: Twenty-five patients were treated. Treatment was well tolerated. The median duration of treatment was 184 days. Diarrhea was the most significant toxicity. Three patients experienced substantial myelosuppression. The steady-state plasma pharmacokinetics of vandetanib was comparable with previous studies. Although the plasma exposure to dasatinib decreased from days 8 to 42, it remained similar to adult studies. CSF to plasma exposure of vandetanib and dasatinib were approximately 2% in 2 patients. Phosphorylated 70S6K decreased during therapy in PBMCs. Conclusions: The MTD of vandetanib and dasatinib in combination was 65 mg/m2 for each drug. Other studies are underway to test dasatinib and other PDGFR inhibitors alone or in combination for this deadly cancer.

Original languageEnglish (US)
Pages (from-to)3050-3058
Number of pages9
JournalClinical Cancer Research
Volume19
Issue number11
DOIs
StatePublished - Jun 1 2013

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma'. Together they form a unique fingerprint.

  • Cite this

    Broniscer, A., Baker, S. D., Wetmore, C., Pai Panandiker, A. S., Huang, J., Davidoff, A. M., Onar-Thomas, A., Panetta, J. C., Chin, T. K., Merchant, T. E., Baker, J. N., Kaste, S. C., Gajjar, A., & Stewart, C. F. (2013). Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clinical Cancer Research, 19(11), 3050-3058. https://doi.org/10.1158/1078-0432.CCR-13-0306